Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications
NCT04374487
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
COVID 19
Interventions
DRUG:
Convalescent Plasma
OTHER:
Standard Care Therapy
Sponsor
Max Healthcare Insititute Limited